Výsledky vyhledávání - "Laxman B. Bahroo"

AbobotulinumtoxinA using 2-mL dilution (500 U/2-mL) maintains durable improvement across multiple treatment cycles

Autor: Pascal Maisonobe, Bruce Rubin, Khashayar Dashtipour, Richard Trosch, Stefan Wietek, Laxman B. Bahroo

Publikováno v: Journal of Clinical Movement Disorders, Vol 7, Iss 1, Pp 1-7 (2020)
Journal of Clinical Movement Disorders

Background Cervical dystonia (CD), the most common focal dystonia, is a chronic neurological movement disorder characterized by sustained involuntary contractions of the neck muscles, leading to abnormal postures. AbobotulinumtoxinA (aboBoNT-A) was a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6207d1b959aba4b5aaa6fa4b6c0978a2
http://link.springer.com/article/10.1186/s40734-020-00090-x

Zobrazit plný text záznamu

Perspective of an International Online Patient and Caregiver Community on the Burden of Spasticity and Impact of Botulinum Neurotoxin Therapy: Survey Study (Preprint)

Autor: Atul T Patel, Theodore Wein, Laxman B Bahroo, Ophélie Wilczynski, Carl D Rios, Manuel Murie-Fernández

BACKGROUND Patient- and caregiver-reported data are lacking on the burden of spasticity, and the impact of botulinum neurotoxin type A (BoNT-A) treatment for this condition, on patients' daily lives. As recommended in recent guidance from the US Food

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::55653dcb136892bb13b4097ad26229bc
https://doi.org/10.2196/preprints.17928

Zobrazit plný text záznamu

AbobotulinumtoxinA provides flexibility for the treatment of cervical dystonia with 500 U/1 mL and 500 U/2 mL dilutions

Autor: Robert A. Hauser, William G. Ondo, Laxman B. Bahroo, Mark F. Lew, Daniel Truong, Atul T. Patel, Allison Brashear, Pascal Maisonobe, Stefan Wietek, Stuart Isaacson, Khashayar Dashtipour

Publikováno v: Clinical Parkinsonism & Related Disorders, Vol 5, Iss, Pp 100115-(2021)
Clinical Parkinsonism & Related Disorders

Highlights • Cervical dystonia has significant impact on quality of life of those affected. • Dilution options allow for treatment flexibility and individualized patient care. • AboBoNT-A is efficacious with similar safety and tolerability at e

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::470fdeaaa19647d9399f5a447de52123
https://doi.org/10.1016/j.prdoa.2021.100115

Zobrazit plný text záznamu

Perspective of an International Online Patient and Caregiver Community on the Burden of Spasticity and Impact of Botulinum Neurotoxin Therapy: Survey Study

Autor: Ophélie Wilczynski, Carl Rios, Manuel Murie-Fernandez, Laxman B. Bahroo, Atul T. Patel, Theodore Wein

Publikováno v: JMIR Public Health and Surveillance
JMIR Public Health and Surveillance, Vol 6, Iss 4, p e17928 (2020)

Background Patient- and caregiver-reported data are lacking on the burden of spasticity, and the impact of botulinum neurotoxin type A (BoNT-A) treatment for this condition, on patients' daily lives. As recommended in recent guidance from the US Food

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ea056371f44042a97bb6eba1aa83ad0
https://doi.org/10.2196/17928

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání